Seres Therapeutics, Inc.

Seres Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops live biotherapeutic product candidates designed to treat and prevent infections and inflammatory and immune diseases. The company engineers oral consortia of cultivated bacteria to restore gastrointestinal barrier integrity, induce immune homeostasis, and prevent pathogen colonization. Its pipeline includes investigational candidates such as SER-155, which addresses bloodstream infections and immune-related enterocolitis, as well as SER-603 and SER-147 for inflammatory bowel diseases and metabolic conditions. Target populations comprise medically vulnerable patients, including individuals undergoing stem cell transplantation, cancer patients on immune checkpoint inhibitors, and people with chronic liver disease.

The company conducts research and development activities and operates dedicated good manufacturing practices capabilities for its live biotherapeutic candidates. It is actively evaluating opportunities across diverse clinical indications, including intensive care, oncology, and transplant settings. Seres Therapeutics maintains its principal executive offices in Cambridge, Massachusetts.

Summary of the business section of Seres Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 66 full-time permanent employees, which included 14 employees in operations and administration and 52 employees in research and development (which includes clinical and manufacturing).”